MOLBIO (MOLBIO)
Active threads
Motilal Oswal initiates Molbio Diagnostics with Buy, ₹1,800 target
4 Min Read Shares of Molbio Diagnostics Ltd. rose as much as 3% on Monday, October 5, as brokerage firm Motilal Oswal Financial Services initiated coverage on the recently listed diagnostics company with a "Buy" rating and a target price of ₹1,800. The target implies a 19% upside from last Thursday's closing price of ₹1,513.10, as per their base case scenario.
Molbio jumps 9% as Jefferies initiates Buy with Rs 1,600 target
Molbio gains 9% as Jefferies assigns 'Buy' tag on innovation-led model Calling Molbio a 'high-conviction pick', Jefferies has set a target price of ₹1,600 on the counter, signalling an upside of 27 per cent from its last closing price of ₹1255.60 apiece. Listen to This Article Molbio Diagnostics share price: Med-tech company Molbio Diagnostics' shares rallied 9 per cent in Wednesday's trading session after Jefferies initiated coverage with a 'Buy' rating on the back of its innovative model.
Molbio Diagnostics Surges 21% on Market Debut
Molbio Diagnostics shares listed at a 21% premium over its IPO price, with the stock continuing to gain in early trading. The strong debut follows a positive response to the IPO, and the company is now trading well above its issue price. The listing is part of a broader trend of strong market debuts, with Dhoot Transmission also gaining 38%.
Motilal Oswal initiates Molbio Diagnostics coverage with Buy rating
Molbio has built its business around Truenat, a portable molecular testing platform that enables point-of-care testing with limited infrastructure. The platform has more than 12,500 devices across over 90 countries and offers 43 assays covering 30 diseases. Why Truenat remains key to Molbio's growth The biggest part of the thesis is not the sale of diagnostic devices, but the recurring revenue generated from test kits.
World Bank, HDFC AMC back Molbio Diagnostics IPO
IFC, the private-sector investment arm of the World Bank Group, last participated as an anchor investor in an Indian IPO in June 2021, when it invested Rs 10 crore in Dodla Dairy. According to news reports, IFC stayed invested in Dodla Dairy for three years until 2024. The investment marks a notable institutional endorsement for Molbio Diagnostics, which is regarded as Goa's first unicorn and is backed by Temasek and Motilal Oswal Private Equity.
Intelligence feed
No articles in the last 24 hours.